Global Brain Tumour Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Therapy (Chemotherapy, Gene therapy), By Type (PET-CTScan, Lumbar Puncture), By Application (Dermatology, Cardiology), By End User (Hospitals, Oncology Treatment Centers), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030Industry: Healthcare
Global Brain Tumour Therapeutics Market Insights Forecasts to 2030
- The Brain Tumour Therapeutics market was valued at USD 1.10 Billion in 2021.
- The market is growing at a CAGR of 11.18% from 2022 to 2030
- The global Brain Tumour Therapeutics market is expected to reach USD 2.90 Billion by 2030
- Europe is expected to grow the fastest during the forecast period
Get more details on this report -
The global Brain Tumour Therapeutics market is expected to reach USD 2.90 Billion by 2030, at a CAGR of 11.18% during the forecast period 2022 to 2030.
When brain cells proliferate uncontrollably and form tumours, brain cancer is the result. With this situation, cancerous cells grow in the brain tissue. A tumour is created when cancer cells multiply and cause disruptions in the brain's ability to control sensation, muscle movement, memory, and other basic functions. Cancer cells that develop from brain tissue are known as primary brain tumours, but cancer cells that spread to the brain from other parts of the body are known as metastatic or secondary brain tumours. The therapy for a brain tumour will depend on the size, nature, and location of the tumour as well as any symptoms, general health, and therapeutic preferences. This is referred to as a multidisciplinary team. Your care team may include physician assistants, oncology nurses, nurse practitioners, pharmacists, counsellors, dietitians, social workers, rehabilitation experts, and other medical specialists. Having a care team with experience treating patients with brain tumours is essential, and this may include consulting with doctors outside of your local area to help with diagnosis and treatment planning. With a low-grade brain tumour, surgery can be the only treatment option, especially if the entire tumour can be removed. If the tumour is still visible after surgery, radiation therapy or chemotherapy may be used. While treating higher-grade malignancies, surgery is typically followed by radiation therapy and chemotherapy as the initial step.
This research report categorizes the market for Brain Tumour Therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Brain Tumour Therapeutics market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Brain Tumour Therapeutics market.
Global Brain Tumour Therapeutics Market Report Coverage
|Market Size in 2021:||USD 1.10 Billion|
|Forecast Period 2021-2030 CAGR:||11.18%|
|2030 Value Projection:||USD 2.90 Billion|
|Historical Data for:||2017-2020|
|No. of Pages:||190|
|Tables, Charts & Figures:||130|
|Segments covered:||By Therapy, By Type, By Application, By End User, By Region, and COVID-19 Impact Analysis|
|Companies Covered:||Pfizer Inc., Mayo Foundation for Medical Education and Research (MFMER)., GENERAL ELECTRIC COMPANY, AstraZeneca, Merck & Co., Inc., Siemens Healthcare Private Limited, Carestream Health., Hitachi, Ltd., Koninklijke Philips N.V., Shimadzu Corporation, CANON MEDICAL SYSTEMS CORPORATION, Eisai Co., Ltd., Elekta AB , Varian Medical Systems, Inc. FUJIFILM Corporation, NantOmics., Hologic, Inc., Thermo Fisher Scientific Inc., Genentech, Inc., Bristol-Myers Squibb Company|
|Pitfalls & Challenges:||Covid-19 Impact Analysis|
Get more details on this report -
Technological advancements and advancements in diagnostic equipment are predicted to be the market size drivers for the expansion of brain cancer diagnostics. Also, in the following years, it is anticipated that the global significance of the growth in brain cancer will increase. Technological advancements and advancements in diagnostic equipment are predicted to be the market size drivers for the expansion of brain cancer diagnostics. Also, in the following years, it is anticipated that the global significance of the growth in brain cancer will increase. The market size has been impacted by the increase in cigarette smokers who are at risk of developing brain cancer. Yet, significant obstacles include high diagnostic costs, little awareness, and limited accessibility.
For the expansion of brain tumour diagnosis and treatment in the aforementioned expected timeframe, high treatment costs and a shortage of experts with the necessary training are likely to serve as market barriers. The biggest and most important obstacle to the market's expansion will be problems with product approval and commercialization.
- In 2021, the immunotherapy segment is dominating the market with the largest market share.
Based on the therapy, the global brain tumour therapeutics market is segmented into Chemotherapy, Gene therapy, Immunotherapy, and Others. Among these, the immunotherapy segment is dominating the market with the largest market share. The practise of activating or suppressing the immune system to treat disease is known as immunotherapy. An innovative new form of immunotherapy that improves the immune system's capacity to combat cancer is vaccination. The most frequent primary malignant brain tumour in adults, glioblastoma multiforme, has been shown to respond well to immunotherapy. Hence, it is anticipated that segment expansion will be fueled by expanded R&D initiatives to develop immunotherapeutics to treat brain tumours as well as ongoing government support for the creation of prospective medicines.
- In 2021, the MRI segment holds the largest market share over the forecast period.
On the basis of type, the global brain tumour therapeutics market is segmented into MRI, CT Scan (Computer Topography), PET-CT Scan, Lumbar Puncture, Molecular testing, Cerebral Arteriogram, Tissue sampling, and EEG. Among these, the MRI segment holds the largest market share over the forecast period. These devices are used by many neurologists because to their accuracy in analysis. Also, they give clear pictures of the structure of the brain, which are helpful in accurately identifying the location of potentially cancerous tissue. A combination of CT scanning and PET technology is used to perform lump examinations on patients who are receiving therapy. A PET-CT scan is routinely used to diagnose conditions when a CT scan or an MRI are insufficient.
- In 2021, Orthopedic & Musculoskeletal Disorders is dominating the market with the largest market share.
On the basis of application, the global brain tumour therapeutics market is segmented into Orthopedic & Musculoskeletal Disorders, Dermatology, Cardiology, Central Nervous System Diseases, Oncology, and Diabetes. Among these, orthopedic and musculoskeletal disorders is dominating the market with the largest market share over the forecast period. Orthopedic physicians typically address these conditions. They can result in mild pains, joint stiffness, edoema, and recurring pain. Moreover, this may restrict your range of motion and obstruct essential daily tasks including walking, typing, lifting, and holding objects.
- In 2021, the Oncology Treatment Centers segment is dominating the market over the forecast period.
On the basis of end user, the global brain tumour therapeutics market is segmented into Hospitals, Oncology Treatment Centers, and Others. Among these, oncology treatment centers segment is dominating the market over the forecast period. The most thorough programmes for cancer detection and treatment are run by oncology treatment centres. Cancer patients receive care by oncologists. These oncologists work together with specialists from all other disciplines to offer coordinated, integrated, multidisciplinary care to cancer patients.
Regional Segment Analysis of the Brain Tumour Therapeutics Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share over the forecast period.
Get more details on this report -
The North American Brain Tumor Therapies Market is anticipated to have a sizable share over the forecast period. The sophisticated healthcare sector in the United States, along with a rising awareness of current technology among the local population, is anticipated to dominate the market. Meningiomas are the most frequent type of brain tumour, followed by gliomas. Eflornithine has been recognised as a breakthrough therapy for the treatment of anaplastic glioma and is an orphan drug in the United States. During the anticipated time, this is predicted to have a favourable effect on market growth.
- In April 2022, The precision oncology drug VitrakviTM (larotrectinib) from Bayer has received approval in China for the treatment of recurrent or advanced solid tumours in both adults and children that have NTRK fusion positivity.
- In April 2022, GSK has contracted with PathAI to apply digital pathology AI to cancer and NASH drug research.
The report offers the appropriate analysis of the key organizations/companies involved within the global Brain Tumour Therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Pfizer Inc.
- Mayo Foundation for Medical Education and Research (MFMER).
- GENERAL ELECTRIC COMPANY
- Merck & Co., Inc.
- Siemens Healthcare Private Limited
- Carestream Health.
- Hitachi, Ltd.
- Koninklijke Philips N.V.
- Shimadzu Corporation
- CANON MEDICAL SYSTEMS CORPORATION
- Eisai Co., Ltd.
- Elekta AB
- Varian Medical Systems, Inc.
- FUJIFILM Corporation
- Hologic, Inc.
- Thermo Fisher Scientific Inc.
- Genentech, Inc.
- Bristol-Myers Squibb Company
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2021 to 2030. Spherical Insights has segmented the global Brain Tumour Therapeutics market based on the below-mentioned segments:
Brain Tumour Therapeutics Market, By Therapy
- Gene therapy
Brain Tumour Therapeutics Market, By Type
- CT Scan (Computer Topography)
- PET-CT Scan
- Lumbar Puncture
- Molecular testing
- Cerebral Arteriogram
- Tissue sampling
Brain Tumour Therapeutics Market, By Application
- Orthopedic & Musculoskeletal Disorders
- Central Nervous System Diseases
Brain Tumour Therapeutics Market, By End User
- Oncology Treatment Centers
Brain Tumour Therapeutics Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?